A novel insight into the neuroprotective effects of cannabidiol: maintained apelin/dopamine synthesis, NRF2 signaling, and AKT/CREB/BDNF gene expressions
Acta Neurobiologiae Experimentalis · 2024
DOI: 10.55782/ane-2024-2546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neurobiologiae Experimentalis, 2024. Verfasst von Melike Doğan Ünlü und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey. Hauptthemen laut MEDLINE: Cannabidiol, Neuroprotective Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroinflammation is a process associated with degeneration and loss of neurons in different parts of the brain. The most important damage mechanisms in its formation are oxidative stress and inflammation. This study aimed to investigate the protective effects of cannabidiol (CBD) against neuroinflammation through various mechanisms. Thirty‑two female rats were randomly divided into 4 groups as control, lipopolysaccharide (LPS), LPS + CBD and CBD groups. After six hours following LPS administration, rats were sacrificed, brain and cerebellum tissues were obtained. Tissues were stained with hematoxylin‑eosin for histopathological analysis. Apelin and tyrosine hydroxylase synthesis were determined immunohistochemically. Total oxidant status and total antioxidant status levels were measured, and an oxidative stress index was calculated. Protein kinase B (AKT), brain-derived neurotrophic factor (BDNF), cyclic‑AMP response element‑binding protein (CREB) and nuclear factor erythroid 2‑related factor 2 (NRF2) mRNA expression levels were also determined. In the LPS group, hyperemia, degeneration, loss of neurons and gliosis were seen in all three tissues. Additionally, Purkinje cell loss in the cerebellum, as well as neuronal loss in the cerebral cortex and hippocampus, were found throughout the LPS group. The expressions of AKT, BDNF, CREB and NRF2, apelin and tyrosine hydroxylase synthesis all decreased significantly. CBD treatment reversed these changes and ameliorated oxidative stress parameters. CBD showed protective effects against neuroinflammation via regulating AKT, CREB, BDNF expressions, NRF2 signaling, apelin and tyrosine hydroxylase synthesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
- Department of Neurology, Private Meddem Hospital, Isparta, Turkey.
- Department of Medical Pharmacology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
- Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
- Department of Medical Pharmacology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey; Natural Products Application and Research Center (SUDUM), Suleyman Demirel University, Isparta, Turkey.
Zitieren
APA
Doğan Ünlü, M., Aşçı, S., İmeci, O., Milletsever, A., Özmen, Ö., Sezer, S., & Demirci, S. (2024). A novel insight into the neuroprotective effects of cannabidiol: maintained apelin/dopamine synthesis, NRF2 signaling, and AKT/CREB/BDNF gene expressions. Acta Neurobiologiae Experimentalis. https://doi.org/10.55782/ane-2024-2546
Vancouver
Doğan Ünlü M, Aşçı S, İmeci O, Milletsever A, Özmen Ö, Sezer S, et al. A novel insight into the neuroprotective effects of cannabidiol: maintained apelin/dopamine synthesis, NRF2 signaling, and AKT/CREB/BDNF gene expressions. Acta Neurobiologiae Experimentalis. 2024. doi:10.55782/ane-2024-2546
BibTeX
@article{Doannl2024,
author = {Doğan Ünlü, Melike and Aşçı, Sanem and İmeci, Orhan and Milletsever, Adem and Özmen, Özlem and Sezer, Serdar and Demirci, Serpil},
title = {A novel insight into the neuroprotective effects of cannabidiol: maintained apelin/dopamine synthesis, NRF2 signaling, and AKT/CREB/BDNF gene expressions},
journal = {Acta Neurobiologiae Experimentalis},
year = {2024},
doi = {10.55782/ane-2024-2546}
}
EUVIMED